Abstracts tagged "fibromyalgia and pain management"

Abstract Number: 74 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics of Fibromyalgia in a Chronic Pain Population
Mark Gostine¹, Fred Davis¹, Bradley Roberts², Rebecca Risko², Joseph Cappelleri³, Michael Asmus⁴, Andrew Clair⁵ and Alesia Sadosky⁶, ¹Michigan Pain Consultants, PC, Grand Rapids, MI, ²ProCare Systems, Inc., Grand Rapids, MI, ³Biostatistics, Pfizer, Inc., Groton, CT, ⁴North American Medical Affairs, Pfizer, Inc., Middleton, WI, ⁵Pfizer Inc., New York, NY, ⁶Pfizer Inc,, New York, NY
Background/Purpose: The study’s purpose was to advance the understanding and treatment of fibromyalgia (FM) for patients in a chronic pain management center. FM is a…
Abstract Number: 916 • 2015 ACR/ARHP Annual Meeting
Assessing Alternative Selection Criteria for Fibromyalgia Patients within a Multicenter Chronic Pain Claims Database
Mark Gostine¹, Fred Davis¹, Bradley Roberts², Rebecca Risko², Joseph Cappelleri³, Michael Asmus⁴, Andrew Clair⁵ and Alesia Sadosky⁶, ¹Michigan Pain Consultants, PC, Grand Rapids, MI, ²ProCare Systems, Inc., Grand Rapids, MI, ³Biostatistics, Pfizer, Inc., Groton, CT, ⁴North American Medical Affairs, Pfizer, Inc., Middleton, WI, ⁵Pfizer Inc., New York, NY, ⁶Pfizer Inc,, New York, NY
Background/Purpose: Diagnosing FM is difficult because there is no specific laboratory test to confirm the disorder. Billing practices dictate that physicians assign ICD-9-CM (Corresponding International…
Abstract Number: 1109 • 2013 ACR/ARHP Annual Meeting
Which Baseline Characteristics Influence The Response To Milnacipran In Patient With Fibromyalgia ?
Olivier Vitton¹, Olivier Vitton¹, Pierre Bunouf², Lilia Abtroun³ and Frederic Bonfils¹, ¹Pierre Fabre, Castres, France, ²Pierre Fabre, Toulouse, France, ³Ariana Pharma, Paris, France
Background/Purpose: Milnacipran (MLN) has demonstrated its benefit in treating patients with fibromyalgia. Fibromyalgia is a persistent pain condition that aggregates numerous symptoms (pain, fatigue, sleep…
Abstract Number: L6 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety of Pregabalin in Patients with Fibromyalgia and Co-Morbid Depression Receiving Concurrent Antidepressant Therapy: A Randomized, 2-Way Crossover, Double-Blind, Placebo-Controlled Study
Lesley M. Arnold¹, Piercarlo Sarzi-Puttini², Pierre Arsenault³, Tahira Khan⁴, Pritha Bhadra Brown⁵, Andrew Clair⁵, Joseph Driscoll⁴, Jaren Landen⁴ and Lynne Pauer⁴, ¹Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, ²Azienda Ospedaliera Polo Universitario L. Sacco, Milano, Italy, ³Département de Médecine de Famille, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY
Background/Purpose: Fibromyalgia (FM) is characterized by chronic widespread pain and often associated with mood disorders including depression. Approximately 50–70% of FM patients have a lifetime…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].